Mounjaro®
Starting from £179.99/mo
Start journey Learn moreWegovy can genuinely produce less weight loss than expected — or, rarely, almost none at all — even when taken exactly as prescribed. That is not a myth, and it does not mean you did anything wrong. Research shows that most people lose meaningful weight on semaglutide 2.4mg, but the range is wide: some lose 20% or more of their body weight, others lose 5% or less. Understanding why Wegovy does not work the same way for everyone is the first step to working out what to do about it. These are prescription-only medicines, so any decision about adjusting, continuing or switching treatment rests with your prescriber.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The most common reason people conclude that Wegovy does not work is simply that they are early in the process and comparing themselves to an average that hides an enormous spread. The STEP 1 trial, published in the New England Journal of Medicine, found that adults on semaglutide 2.4mg lost roughly 15% of their body weight over 68 weeks, but that figure is a mean drawn from a population where outcomes ranged considerably.
Titration also confuses the picture. The starting doses of Wegovy exist to reduce nausea and give your digestive system time to adjust; they are not the doses at which meaningful weight loss is expected. Expecting significant results at 0.25mg or 0.5mg is like judging a book by the cover page. The therapeutic window is the maintenance dose, and reaching it takes a minimum of five months of stepping up.
So if you are on week six and feeling underwhelmed, it is almost certainly too early to draw any conclusions. Whether genuine non-response is happening is a question for the maintenance-dose period, not the titration phase. Patience here is not passive, it is part of the clinical logic.
There are real, physiological explanations for why Wegovy does not work equally well across the population, with GLP-1 receptor sensitivity varying between individuals at a genetic level. People with variants that reduce receptor responsiveness may see less appetite suppression even at full dose. This is an active area of research rather than a settled science, but it is a plausible and increasingly recognised mechanism.
Gut-emptying rate also matters. Semaglutide slows gastric emptying to extend the feeling of fullness. In people whose gastric motility is already sluggish (which can be associated with conditions like gastroparesis) the incremental benefit of further slowing may be smaller, and tolerability problems may emerge sooner, limiting how far the dose can be increased.
Hormonal context is relevant too. Insulin resistance, elevated cortisol, and certain thyroid conditions can counteract the metabolic benefits of GLP-1 medicines. Some people's biology makes semaglutide a harder tool to use, not an impossible one, but a harder one. A prescriber looking at the whole clinical picture, including bloodwork, can spot these factors in a way that no self-assessment can.
Then there are medicines. Several commonly prescribed drugs (including some antidepressants, antipsychotics, corticosteroids and insulin sensitisers) are associated with weight gain or weight-loss resistance. Semaglutide can work against a pharmacological headwind. That is worth an honest conversation with whoever manages your other prescriptions.
This is where the misconception runs the other way. Some people assume that because Wegovy is a medical treatment, they do not need to change anything else. The licence for semaglutide is as an adjunct to a reduced-calorie diet and increased physical activity, and the trial evidence was gathered in participants who also received lifestyle support. NHS guidance on semaglutide is clear that diet and activity remain part of the treatment.
That said, the appetite-suppression effect of semaglutide is genuine and significant for most people. If you are eating substantially less without trying, that is the medicine doing its job. If appetite has not shifted noticeably after reaching maintenance dose, that is worth flagging to your prescriber.
Alcohol consumption is underappreciated here. Alcohol is calorie-dense, disrupts sleep (which affects hunger hormones), and can impair the metabolic improvements the medicine is working to achieve. Reducing it is not a moral instruction, it is practical information about what compounds the medicine's effect and what works against it. Sustainable weight loss is almost always multifactorial, and semaglutide works best as part of a fuller picture.
Some people also notice that the appetite suppression becomes less pronounced after several months at the same dose. This is not unusual. It does not necessarily mean the medicine has stopped working altogether (plateau phases are common in weight management) but it is a good reason to review progress with a prescriber rather than simply carrying on.
NICE guidance on semaglutide (Wegovy) states that if a patient has not lost at least 5% of their body weight after six months at the maintenance dose, continuing treatment should be reviewed. That is a clinical checkpoint, not a deadline, it exists to ensure people are not kept on a medicine that is providing no meaningful benefit.
If you reach that point, the conversation with your prescriber might go several ways. Checking that the medicine is being taken correctly is the starting point, oral medicines and injections both have administration details that, if missed, can reduce effectiveness significantly. If you have been asking yourself why Wegovy did not work for you, our dedicated guide walks through the most common individual factors in detail and can help you and your prescriber identify whether any are modifiable.
An alternative medicine is another option. Tirzepatide (Mounjaro) acts on two receptor pathways (GLP-1 and GIP) where semaglutide acts on one. Head-to-head trial data from SURMOUNT-5 showed greater average weight loss with tirzepatide compared to semaglutide 2.4mg over 72 weeks. Whether that difference would apply to you specifically is a clinical judgement, not a guarantee, and your prescriber is the right person to make it. You can read more about semaglutide or explore the full range of licensed weight-loss treatments we offer, if you would like a prescriber to review your situation, checking your eligibility is a straightforward place to start.
If you have specific concerns or would prefer to talk through your experience, our team is available seven days a week and will point you in the right direction without any pressure to proceed.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.